Category: Oral MS Medications

Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects

BARCELONA, July 19, 2011 /PRNewswire/ — – NT-KO-003, developed by Advancell and Neurotec Pharma, is the first MS drug with…

Stuart Schlossman

Laquinimod: The next oral agent for multiple sclerosis?

Key point: According to a Phase III trial of the once-daily, investigational immunomodulatory laquinimod, this agent significantly reduced annualized relapse rate,…

Stuart Schlossman

Merck Serono has decided to not pursue approval for Oral Cladribine

June 22, 2011 Merck Serono announced today that it has decided not to pursue approval of its oral therapy Cladribine…

Stuart Schlossman

Positive Reports from two Phase III Trials BG-12 & Laquinimod Backed by Promising Data

Oral BG-12 In a recent press release, Biogen Idec reported that their oral MS disease-modifier, BG-12, significantly reduced the number…

Stuart Schlossman

FAMPYRA (Ampyra) – has been approved in Australia, To (potentially) Improve Walking Ability In Adult Patients With MS

May 16, 2011 The Australian Therapeutic Goods Administration (TGA) has granted approval for FAMPYRA™, (fampridine) 10 mg Modified Release (MR)…

Stuart Schlossman

As Adoption Deepens Among Prescribers, Satisfaction with Gilenya Remains Muted Due to Continuing Issues with Novartis Support, Managed Care Coverage, and Safety Perceptions, According to a Recent Report from BioTrends

May 16, 2011 EXTON, Penn.–(BUSINESS WIRE)–At six months post launch, market share of Novartis’ Gilenya, the newest disease-modifying agent (DMA)…

Stuart Schlossman

An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis (TOWER)

I just learned of this study and wanted to share it with you, since this is a potential future ORAL…

Stuart Schlossman

AAN: Laquinimod Reduces Multiple Sclerosis Activity

The immunomodulator laquinimod appears to reduce the relapse rate and delay the progression of disability in individuals with multiple sclerosis,…

Stuart Schlossman

Biogen Idec’s oral multiple sclerosis candidate, BG-12 (dimethyl fumarate), met its primary endpoint in the first of two Phase III pivotal trials in patients with relapsing-remitting disease

April 12, 2011 – Biogen Idec’s oral multiple sclerosis candidate, BG-12 (dimethyl fumarate), met its primary endpoint in the first…

Stuart Schlossman

Potential New MS PIll: Experimental medication slowed the rate of brain atrophy and disease progression and relapse, study found

A new oral medication for the treatment of multiple sclerosis (MS) shows promise in slowing disease progression, limiting brain atrophy…

Stuart Schlossman

Categories

Latest Blog Posts